Christina Ackermann, a Senior Officer, acquired 6,819 Common Shares on a direct ownership basis at a price of $23.560USD through an exercise of rights on March 8th, 2019. This represents a $215,632 investment into the company's shares and an account share holdings change of greater than 100%.
Thomas Appio, a Senior Officer, acquired 7,387 Common Shares on a direct ownership basis at a price of $23.560USD through an exercise of rights on March 8th, 2019. This represents a $233,593 investment into the company's shares and an account share holdings change of 14.8%.
Osama Eldessouky, a Senior Officer, acquired 3,551 Common Shares on a direct ownership basis at a price of $23.560USD through an exercise of rights on March 8th, 2019. This represents a $112,291 investment into the company's shares and an account share holdings change of 27.3%.
Joseph Gordon, a Senior Officer, acquired 4,546 Common Shares on a direct ownership basis at a price of $23.560USD through an exercise of rights on March 8th, 2019. This represents a $143,755 investment into the company's shares and an account share holdings change of 37.1%.
Paul Herendeen, CFO, acquired 19,889 Common Shares on a direct ownership basis at a price of $23.560USD through an exercise of rights on March 8th, 2019. This represents a $628,935 investment into the company's shares and an account share holdings change of 20.4%.
Mark McKenna, a Senior Officer, acquired 2,841 Common Shares on a direct ownership basis at a price of $23.560USD through an exercise of rights on March 8th, 2019. This represents a $89,839 investment into the company's shares and an account share holdings change of greater than 100%.
Joseph Papa, CEO and Director, acquired 37,884 Common Shares on a direct ownership basis at a price of $23.560USD through an exercise of rights on March 8th, 2019. This represents a $1,197,977 investment into the company's shares and an account share holdings change of 9.3%.
Bausch Health Companies is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.
No Comments